Filing Flows › Beta Bionics (BBNX) › Q1 2026
Beta Bionics (BBNX) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 21, 2026
Beta Bionics (BBNX) reported revenue of $27.6M for the first quarter 2026 (Q1 2026), +57% from a year earlier and -14% from the quarter before. Operating margin was -87.9%, net loss $21.9M (79.3% of revenue).
Beta Bionics, Q1 2026: revenue $27.6M (+57% year over year), operating margin -87.9%, net loss $21.9M, operating cash flow −$23.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.6M | -14% | +57% |
| Operating profit | −$24.3M | — | — |
| Net earnings | −$21.9M | — | — |
| Operating cash flow | −$23.8M | — | — |
What changed
Revenue was $27.6M in Q1 2026, up 57% year over year and down 14% from the previous quarter.
Gross margin was 59.5%, up 8.6 points from Q1 2025. Operating costs exceeded revenue by $24.3M, an operating margin of -87.9%. Operating expenses grew 47% against revenue growth of 57%. The fastest-growing cost line was Sales & marketing (+55%). The quarter ended with a net loss of $21.9M, wider than the previous quarter's $13.5M loss.
Operating cash flow was −$23.8M. Non-cash charges added back $585K of depreciation and $5.4M of share-based compensation. Working capital and other items used $7.9M. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$25.2M.
Questions
What was Beta Bionics' revenue in the first quarter 2026?
Beta Bionics (BBNX) reported revenue of $27.6M for the first quarter 2026 (Q1 2026), +57% from a year earlier and -14% from the quarter before.
Was Beta Bionics profitable in the first quarter 2026?
Operating loss was $24.3M (-87.9% of revenue) and net loss $21.9M.
Source: Beta Bionics 10-Q on SEC EDGAR.